Search

Your search keyword '"Di Sapio, Alessia"' showing total 186 results

Search Constraints

Start Over You searched for: Author "Di Sapio, Alessia" Remove constraint Author: "Di Sapio, Alessia"
186 results on '"Di Sapio, Alessia"'

Search Results

1. Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA)

3. Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project

4. ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis

5. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

6. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

7. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

8. Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

9. Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study

10. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study

11. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

12. A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis.

13. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

14. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

15. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

18. Cladribine vs other drugs in MS: Merging randomized trial with real-life data

20. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis

21. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies

22. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy

23. Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study

25. Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study

26. sj-docx-1-msj-10.1177_13524585221102918 – Supplemental material for Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies

29. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

30. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

31. Author Correction: Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

32. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

39. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study

43. Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

44. Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience.

45. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study

Catalog

Books, media, physical & digital resources